Skip to main content
S&P 5007,720.39-0.30%DOW52,342.56-0.25%NASDAQ26,184.72-1.38%BTC$77,565.00-3.36%ETH$2,242.34-3.63%GOLD$3,989.90-1.03%OIL$104.17+2.13%
Smart Investors Daily
SID Premium
PR

NASDAQ · PRCT

PROCEPT BioRobotics Corporation

Healthcare · Medical - Devices

$20.30

Up+$0.10 (+0.50%)

Updated Oct 30, 2026, 10:16 AM

SID Score

5.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.01B
P/E ratio
-23.73
Dividend yield
0.00%
52-week range
$16.67 – $38.11
Volume
704.54K
Avg. volume
1.41M

Price performance · PRCT

PRCT price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 29, 2026

PRCT closed at $20.30 after 21 trading sessions, up 19.27% for the selected period.

Last close
$20.30
Period change
+19.27%
Period low
$17.02
Period high
$20.30
Daily close
View OHLC price history
PRCT OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 29, 2026$20.41$20.67$20.06$20.30704.54K
Oct 28, 2026$19.65$20.32$19.65$20.20904.81K
Oct 27, 2026$19.82$19.92$19.43$19.80709.3K
Oct 26, 2026$19.775$20.21$19.36$19.83701.73K
Oct 23, 2026$19.90$20.12$18.75$19.96773.76K
Oct 22, 2026$18.24$20.05$18.23$20.031.19M
Oct 21, 2026$18.54$18.98$18.12$18.27733.18K
Oct 20, 2026$18.32$19.11$18.2226$18.82985.55K
Oct 19, 2026$17.62$18.32$17.53$18.281.01M
Oct 16, 2026$18.35$18.67$17.52$17.571.2M
Oct 15, 2026$17.58$18.225$17.58$18.151.25M
Oct 14, 2026$19.00$19.02$17.49$17.511.73M
Oct 13, 2026$19.73$19.87$18.684$19.101.81M
Oct 12, 2026$18.48$19.80$18.46$19.572.05M
Oct 9, 2026$17.78$18.44$17.78$18.401.11M
Oct 8, 2026$17.80$18.03$17.52$17.901.18M
Oct 7, 2026$17.63$18.46$17.63$17.911.15M
Oct 6, 2026$17.82$18.00$17.22$17.51949.62K
Oct 5, 2026$17.16$18.09$17.125$17.82970.97K
Oct 2, 2026$17.19$17.905$16.95$17.161.24M
Oct 1, 2026$18.26$18.46$16.74$17.021.6M

Latest PRCT news

The latest Smart Investors Daily articles mentioning PRCT.

Stock researchCompany · Overview

PRCT research

Overview

Company profile and research snapshot.

Company profile

PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$54.14
Implied upside
—
Analysts
19
PRCT recent ratings
DateFirmRatingTarget
Oct 7, 2026BarclaysOverweight—
Aug 5, 2026William BlairMarket Perform—
Aug 5, 2026Piper SandlerOverweight—
Aug 5, 2026TD CowenBuy—
Aug 5, 2026Evercore ISI GroupOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 12, 2026

PROCEPT BioRobotics® to Report Third Quarter 2026 Financial Results on November 4th, 2026

SAN JOSE, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2026 after market close on Wednesday, November 4, 2026. The Company’s management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to

Yahoo · Oct 8, 2026

PROCEPT BioRobotics (PRCT) Could Be 70% Undervalued On Lawsuit And Board Change

Why this governance shift at PROCEPT BioRobotics matters for investors A fresh investor lawsuit and the appointment of cardiac surgeon Dr. Michael Mack to the board put PROCEPT BioRobotics (PRCT) under a governance spotlight that stockholders will want to understand closely. Recent trading tells a story of pressure rather than momentum for PROCEPT BioRobotics, with the share price delivering a 30 day return of down 21.31% and a year to date share price return of down 41.77%. The 1 year total...

Yahoo · Oct 6, 2026

Does New Director and Discounting Lawsuit Change The Bull Case For PROCEPT BioRobotics (PRCT)?

In early October 2026, PROCEPT BioRobotics added veteran cardiac surgeon Dr. Michael Mack to its board as an independent Class II director, while also facing a newly filed securities lawsuit alleging undisclosed discounting practices that inflated reported U.S. handpiece demand and related operational risks. The combination of a medically seasoned, research-focused director and allegations about bulk-order discounting practices raises important questions about PROCEPT’s governance,...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By